Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Corticospinal adaptations following resistance training and its relationship with strength: A systematic review and multivariate meta-analysis

  • Gómez-Feria, José
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., Neural adaptations to resistance training (RT) and their correlation with muscle strength remain partially understood. We conducted a systematic review and multivariate meta-analysis to examine the effects of metronome-paced (MP), self-paced (SP), and isometric (IM) training on M1 and corticospinal pathway activity. Following MP RT, a significant increase in corticospinal excitability was observed, correlating with increased strength. Conversely, no significant relationship was found after SP or IM training. RT also reduced the duration of the cortical silent period, but this change did not predict strength changes and was not specific to any training modality. No significant effects were found for short-interval intracortical inhibition. Our findings suggest that changes in corticospinal excitability may contribute to strength gains after RT. Furthermore, the relationship between these adaptations and strength appears dependent on the type of training performed., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. JG-F is supported by the Ministerio de Ciencia e Innovación (Grant FPU16/03550). JFM-R is supported by VI-PPIT-US from the University of Seville (USE-18817-A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease

  • Periñán, María Teresa
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Martín-Rodríguez, Juan Francisco
  • Muñoz-Delgado, Laura
  • Jiménez-Jaraba, María Valle
  • Buiza-Rueda, Dolores
  • Bonilla-Toribio, Marta
  • Adarmes-Gómez, Astrid
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., [Background] Hyperhomocysteinemia is considered an independent risk factor for cognitive impairment., [Objective] To study the correlation between homocysteine levels and cognitive impairment in patients with PD., [Methods] We conducted a case–control study that included 246 patients with PD, of whom 32 were cognitively impaired. The levels of homocysteine, folate, and vitamin B12 were measured in peripheral blood. Multivariate logistic regression analysis was applied to determine differences in homocysteine levels between PD patients with and without cognitive impairment. A meta-analysis was performed to clarify the role of Hcy levels in PD with cognitive decline. Five polymorphisms in genes involved in Hcy metabolism, including MTHFR rs1801133 and rs1801131, COMT rs4680, MTRR rs1801394, and TCN2 rs1801198, were genotyped., [Results] Our case–control study showed that homocysteine levels were associated with cognitive impairment in PD after adjusting for possible confounding factors such as levodopa equivalent daily dose. The results of our meta-analysis further supported the positive association between homocysteine levels and cognition in PD. We found that the MTHFR rs1801133 TT genotype led to higher homocysteine levels in PD patients, whereas the MTHFR rs1801131 CC genotype resulted in higher folate levels. However, the polymorphisms studied were not associated with cognitive impairment in PD., [Conclusions] Increased homocysteine levels were a risk factor for cognitive decline in PD. However, no association was found between polymorphisms in genes involved in homocysteine metabolism and cognitive impairment in PD. Large-scale studies of ethnically diverse populations are required to definitively assess the relationship between MTHFR and cognitive impairment in PD., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], and the Fundación Alicia Koplowitz. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program [C-0048-2017] (from Andalusian Regional Ministry of Health). Silvia Jesús was supported by the "Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias de la Junta de Andalucía [B-0007-2019]. Daniel Macías-García was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). Juan Francisco Martín-Rodríguez was supported by the VI-PPIT-US from the University of Seville [USE-18817-A]. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

How can I assess my patients with Parkinson's disease during a busy clinic day?

  • Cubo, Esther
  • García-Bustillo, Álvaro
  • Calvo, Sara
  • Gámez-Leyva, Gonzalo
  • Simón-Vicente, Lucia
  • Rivadeneyra, Jessica
  • Miranda, Javier
  • Madrigal, Elisabet
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • Santos-García, Diego
  • COPPADIS Study Group
[Background] The evaluation of motor impairment in Parkinson's disease (PD) is mainly assessed with the motor subdomain of the Unified Parkinson's Disease Rating scale (UPDRS part III) and, lately, with the MDS-UPDRS part III. To optimize efforts and special needs during specific circumstances in clinical practice, we sought to identify the most sensitive items to assess motor impairment in PD., [Methods] We included the COPPADIS-PD cohort and collected the UPDRS part III at baseline (V0), 12 months (V1), and 24 months (V2). Factor analysis and effect size using Cohen's d formula were performed in the Off and On states at V0, V1, and V2., [Results] We included 667 patients with PD, mean age of 62.59 ± 8.91 years, 410 (60.2%) males, with a median HY stage of 2.00 (1.00; 4.00) at baseline. Over time, the most discriminating items were postural stability and body bradykinesia (“arise from chair” and “gait”) in the Off state, right and left upper extremity bradykinesia ("finger tap", "hand movements" and "prono/supination") in the On state. Body bradykinesia and right-left finger tapping were the items with the largest effect size (0.93, 0.84, 0.83, respectively) to assess motor improvement after receiving antiparkinsonian medications over time., [Conclusion] Under specific circumstances, selecting a few items of the UPDRS part III, including postural stability, body bradykinesia, and upper extremity bradykinesia, could be used to create a quick clinical judgment of motor status and improvement in PD., This work was supported by the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI20/00613], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Fundación Alicia Koplowitz and the Fundación "Curemos el Parkinson"., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease

  • Muñoz-Delgado, Laura
  • Macías García, Daniel
  • Periñán, María Teresa
  • Jesús Maestre, Silvia
  • Adarmes-Gómez, Astrid
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Jiménez-Jaraba, María Valle
  • Benítez Zamora, Belén
  • Díaz-Belloso, Rafael
  • García-Díaz, Sergio
  • Martín Bórnez, Miguel
  • Pineda-Sánchez, Rocío
  • Carrillo, Fátima
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The present study was aimed at determining if the peripheral inflammatory immune response could be influenced by the genetic background of patients with PD. We included a discovery cohort with 222 patients with PD (132 sporadic PD, 44 LRRK2-associated PD (with p.G2019S and p.R1441G variants), and 46 GBA-associated PD), as well as 299 HCs. Demographic and clinical data were recorded. Leukocytes and their subpopulations, and the NLR were measured in peripheral blood. Multivariate lineal regression and post-hoc tests were applied to determine the differences among the groups. Subsequently, a replication study using the Parkinson’s Progression Markers Initiative cohort was performed which included 401 patients with PD (281 sPD patients, 66 LRRK2-PD patients, 54 GBA-PD patients) and a group of 174 HCs. Patients with sporadic PD and GBA-associated PD showed a significantly lower lymphocyte count, a non-significantly higher neutrophil count and a significantly higher NLR than HCs. The peripheral inflammatory immune response of patients with LRRK2-associated PD did not differ from HCs. Our study supports the involvement of a peripheral inflammatory immune response in the pathophysiology of sPD and GBA-associated PD. However, this inflammatory response was not found in LRRK2-associated PD, probably reflecting different pathogenic inflammatory mechanisms., The authors thank the donors and the Hospital Universitario Virgen del Rocío-Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for the human specimens used in this study. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, and PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases – Project ID No 739510. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017; from the Andalusian Regional Ministry of Health). Silvia Jesús was supported by the “Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias, Junta de Andalucía (B-0007-2019). Daniel Macías-Garcia was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III. Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III. Rafael Díaz Belloso was supported by pre-doctoral contract for training in health research (PFIS) from Instituto de Salud Carlos III. Sergio García Díaz was supported by an University Teacher Training Programme (FPU) from the Spanish Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC

  • García-González, Pablo
  • Díaz Belloso, Rafael
  • Munoz-Delgado, Laura
  • Buiza Rueda, Dolores
  • Gómez-Garre, Pilar
  • Pérez-Tur, Jordi
  • Real, Luis M.
  • Bullido, María Jesús
  • Ruiz, Agustín
18 páginas, 2 figuras, Progressive supranuclear palsy (PSP) is a rare 4-repeat tauopathy that causes behavioural, movement and cognitive abnormalities. We genotyped all available clinical and histopathological PSP cases in Spain and Portugal (N = 522), and conducted the largest PSP GWAS of the Iberian population to date. Genetic burden analysis revealed reduced diagnostic specificity in clinically diagnosed atypical PSP cases-when applying the 2017 MDS criteria-compared to Richardson's syndrome cases. We independently replicated eight PSP risk variants in seven known loci (MAPT, MOBP, EIF2AK3, STX6, SLCO1A2, DUSP10 and APOE), and identified a novel locus in NFASC/CNTN2 (rs12744678 C: OR[95%CI] = 0.83[0.78-0.89]; p = 4.15·10-08) after meta-analysis with a newly available Dutch cohort and publicly available summary statistics (3,099 PSP; 11,482 controls). Enrichment analysis and protein expression profiling highlighted oligodendrocyte function and myelination as likely contributors to PSP pathogenesis. Our findings broaden the genetic landscape of PSP and suggest potential therapeutic avenues focused on modulating neuron-oligodendrocyte interactions., This work was funded by CIBERNED (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R  +  D  +  I Plan and funded by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Agustín Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). He is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer’s and Neurodegenerative Diseases (2025-2028). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF”. Itziar de Rojas received support by a national grant from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and Fundación ADEY under the program “Proyectos de Investigación en Salud 2023”. Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional Development Fund (ERDF) and to Fundacio ́ la Marato ́ de TV3 (PI043296 and 202009-10). This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel Real received support from “The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations” (GEHEP-012 study). Consejería de Salud de la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela Foundation (Sevilla, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HMGCR genetic variability in Parkinson's disease in a Spanish cohort: associations with lipid metabolism and early onset

  • Díaz-Belloso, Rafael
  • Martín Bórnez, Miguel
  • Macías García, Daniel
  • García-Díaz, Sergio
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Pineda-Sánchez, Rocío
  • Muñoz-Delgado, Laura
  • Ojeda, Elena
  • Jesús, Silvia
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
  • Gómez-Garre, Pilar
Lipid metabolism has emerged as a key factor in the pathophysiology of Parkinson’s disease (PD). While 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, has been implicated in neurodegenerative disorders, such as Alzheimer disease, its role in PD remains unexplored. Given the shared pathological features between these neurodegenerative disorders (such as lysosomal dysfunction and lipid dysregulation) we hypothesized that HMGCR genetic variability could influence PD susceptibility and/or phenotypic expression, particularly in early-onset cases (EOPD). Therefore, we performed targeted sequencing of HMGCR in 1162 Spanish PD patients and analyzed associations with PD risk or age at onset. Replication was attempted in 436 PD cases from Parkinson’s Progression Markers Initiative (PPMI). We identified 21 HMGCR variants, including a likely pathogenic variant affecting the splice site of exon 4 (c.278-1G > A) in a patient with early-onset PD (EOPD), rapid progression, and severe dyslipidemia. The rs5908 variant was significantly associated with EOPD in our cohort (OR = 2.22, p = 0.025). Further analysis revealed rs5908 is in linkage disequilibrium with rs115169875, an intronic variant with putative regulatory impact. Our findings nominate HMGCR as a candidate gene for PD development, particularly in early-onset cases. The metabolic profile of the c.278-1G > A carrier parallels GBA-associated PD, suggesting convergent lipid-lysosomal pathways in neurodegeneration. While cohort differences highlight population-specific genetic effects, these findings underscore the importance of lipid pathways in PD and the need to explore HMGCR’s role in PD subtypes with metabolic comorbidity., Funding for open access publishing: Universidad de Sevilla/CBUA. This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150–1), and funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI24/00632), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471–2013, PE-0210–2018, PI-0459–2018, PE-0186–2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048–2017) from Andalusian Regional Ministry of Health. Rafael Díaz Belloso and Miguel Martín Bornez were supported by pre-doctoral contracts for training in health research (PFIS) from Instituto de Salud Carlos III, with grant numbers FI20/00173 and FI22/00226, respectively. Daniel Macías-García was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III (ISCIII- FEDER). Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III (ISCIII- FEDER). Sergio García Díaz was supported by a University Teacher Programme (FPU20/00723) from the Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no competing interests to declare that they are relevant to the content of this article., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease, Imaging results from the COPPADIS study

  • Grothe, Michel|||0000-0003-2600-9022
  • Labrador-Espinosa, Miguel A.|||0000-0003-3576-1777
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Macías-García, Daniel|||0000-0002-4822-1529
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Carrillo, Fátima
  • Iglesias Camacho, Elena
  • Franco-Rosado, Pablo
  • Roldán Lora, Florinda
  • Martín-Rodríguez, Juan Francisco|||0000-0003-1392-8775
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Escalante, Sonia|||0000-0001-8931-1400
  • Soriano Vila, Berta
  • Cots-Foraster, Anna|||0000-0002-9169-7653
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Carrillo Padilla, Francisco
  • Pueyo Morlans, Mercedes
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Infante Ceberio, Jon
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • de Deus Fonticoba, Teresa
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Santos García, Diego|||0000-0002-3126-5111
  • Mir, Pablo|||0000-0003-1656-302X
Introduction: We aimed to assess associations between multimodal neuroimaging measures of cholinergic basal forebrain (CBF) integrity and cognition in Parkinson's disease (PD) without dementia. Methods: The study included a total of 180 non-demented PD patients and 45 healthy controls, who underwent structural MRI acquisitions and standardized neurocognitive assessment through the PD-Cognitive Rating Scale (PD-CRS) within the multicentric COPPADIS-2015 study. A subset of 73 patients also had Diffusion Tensor Imaging (DTI) acquisitions. Volumetric and microstructural (mean diffusivity, MD) indices of CBF degeneration were automatically extracted using a stereotactic CBF atlas. For comparison, we also assessed multimodal indices of hippocampal degeneration. Associations between imaging measures and cognitive performance were assessed using linear models. Results: Compared to controls, CBF volume was not significantly reduced in PD patients as a group. However, across PD patients lower CBF volume was significantly associated with lower global cognition (PD-CRS: r = 0.37, p < 0.001), and this association remained significant after controlling for several potential confounding variables (p = 0.004). Analysis of individual item scores showed that this association spanned executive and memory domains. No analogue cognition associations were observed for CBF MD. In covariate-controlled models, hippocampal volume was not associated with cognition in PD, but there was a significant association for hippocampal MD (p = 0.02). Conclusions: Early cognitive deficits in PD without dementia are more closely related to structural MRI measures of CBF degeneration than hippocampal degeneration. In our multicentric imaging acquisitions, DTI-based diffusion measures in the CBF were inferior to standard volumetric assessments for capturing cognition-relevant changes in non-demented PD.